# A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

> **NCT06393673** · PHASE2 · UNKNOWN · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 195 (estimated)

## Conditions studied

- Vasomotor Symptoms

## Interventions

- **DRUG:** HS-10384 tablet Dose 1
- **DRUG:** HS-10384 tablet Dose 2
- **DRUG:** HS-10384-matched placebo tablets

## Key facts

- **NCT ID:** NCT06393673
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-30
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393673, "A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06393673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*